Mar 25 2011
AlphaRx Inc. (OTC BB:ALRX.OB) has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment. AlphaRx has developed three formulations using ARX8203, an injectable formulation for post-surgical pain, an oral capsule for chronic pain and an ophthalmic formulation for ocular inflammation.
AlphaRx has eight further U.S. patent applications pending in different stages of examination and is confident that this is the first of many patents yet to receive allowance.
Pain reliever use in pregnancy shows no link to child neurodevelopmental disorders, study finds